Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tax2

Preclinical

AApmonia Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Solid Tumor CancersNot yet recruiting

Solid Tumor CancersPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q3 2030

PreclinicalNot yet recruiting

Solid Tumor Cancers

NCT07688148

Clinical

Trials by Indication[1]

Solid Tumor Cancers1 trial

A Phase 1/2a, First-in-human, Open-label, Dose-escalating Study With a Safety Expansion Cohort to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours

Not yet recruiting·AApmonia Therapeutics·Preclinical·NCT07688148·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tax2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tax2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Apmonia Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AApmonia Therapeutics

Related News